Anticalins®: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies

Anticalins® are engineered ligand-binding proteins based on the human lipocalin scaffold. Their architecture is characterized by a rigid β-barrel that supports four structurally hypervariable loops. Similar to antibodies, these loops form the natural ligand-binding site, usually for vitamins, hormones or secondary metabolites. Anticalins with novel specificities can be engineered by reshaping this loop region, using targeted random mutagenesis in combination with functional display and guided selection. Several drug candidates with specificities for exogenous low-molecular-weight substances, peptides and even protein targets (e.g., several disease-related cell surface receptors) have been obtained in this way. Owing to their exquisite specificity and high affinity, Anticalins are particularly attractive as antagonists for the manipulation of immune mechanisms, leading to either inhibitory or stimulatory effects. Compared with antibodies, Anticalins offer several practical advantages as they are much smaller, consist of a single polypeptide chain and can be produced easily in microbial expression systems.

[1]  N. Damle,et al.  Biopharmaceutical drug discovery using novel protein scaffolds. , 2006, Current opinion in biotechnology.

[2]  Arne Skerra,et al.  Construction of an Artificial Receptor Protein (“Anticalin”) Based on the Human Apolipoprotein D , 2004, Chembiochem : a European journal of chemical biology.

[3]  P. Parren,et al.  Immunogenicity screening in protein drug development , 2007, Expert opinion on biological therapy.

[4]  W. Dijk,et al.  α1-Acid Glycoprotein , 1995 .

[5]  A. Wu,et al.  Tailoring antibodies for radionuclide delivery , 2006, Expert opinion on drug delivery.

[6]  S. Gambhir Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[7]  R. Huber,et al.  Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibitor derived from a triatomine bug. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Paesen,et al.  Complement Inhibitor of C5 Activation from the Soft Tick Ornithodoros moubata , 2005, The Journal of Immunology.

[9]  Edward W. Voss,et al.  Fluorescein hapten : an immunological probe , 1984 .

[10]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2006 , 2006, Nature Biotechnology.

[11]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Min Zhang,et al.  Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins* , 2002, The Journal of Biological Chemistry.

[13]  J. Andersen,et al.  Inhibition of Hemostasis by a High Affinity Biogenic Amine-binding Protein from the Saliva of a Blood-feeding Insect* , 2003, The Journal of Biological Chemistry.

[14]  J. Bausch,et al.  Monoclonal antibodies. , 1990, Bioprocess technology.

[15]  I. Korndörfer,et al.  Crystallographic analysis of an “anticalin” with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region , 2003, Proteins.

[16]  B. Comin-Anduix,et al.  Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Gary Walsh,et al.  Biopharmaceutical benchmarks , 2000, Nature Biotechnology.

[18]  L. Steinman Immune Therapy for Autoimmune Diseases , 2004, Science.

[19]  A. Pavlou,et al.  Monoclonal antibodies market , 2004, Nature Reviews Drug Discovery.

[20]  Arne Skerra,et al.  Solubility engineering and crystallization of human apolipoprotein D , 2006, Protein science : a publication of the Protein Society.

[21]  P. Carter Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[22]  Rational engineering of a fluorescein-binding anticalin for improved ligand affinity , 2005, Biological chemistry.

[23]  A. Skerra 'Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties. , 2001, Journal of biotechnology.

[24]  Hubertus Haas,et al.  Human Tear Lipocalin Exhibits Antimicrobial Activity by Scavenging Microbial Siderophores , 2004, Antimicrobial Agents and Chemotherapy.

[25]  B. Nardelli,et al.  Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys , 2002, Journal of Pharmacology and Experimental Therapeutics.

[26]  L. Polito,et al.  Expression of CTLA‐4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin‐mediated apoptosis: results of in vitro studies , 2004, Clinical and experimental immunology.

[27]  A. Skerra Lipocalins as a scaffold. , 2000, Biochimica et biophysica acta.

[28]  J. Andersen,et al.  Purification, Cloning, Expression, and Mechanism of Action of a Novel Platelet Aggregation Inhibitor from the Salivary Gland of the Blood-sucking Bug, Rhodnius prolixus * , 2000, The Journal of Biological Chemistry.

[29]  T. Fournier,et al.  Alpha-1-acid glycoprotein. , 2000, Biochimica et biophysica acta.

[30]  A. Skerra,et al.  Duocalins: Engineered Ligand-Binding Proteins with Dual Specificity Derived from the Lipocalin Fold , 2001, Biological chemistry.

[31]  A. Skerra,et al.  A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. , 2000, Journal of molecular biology.

[32]  B. Ryffel,et al.  Arthropod-Derived Histamine-Binding Protein Prevents Murine Allergic Asthma , 2004, The Journal of Immunology.

[33]  W. Schleuning,et al.  An inhibitor of collagen-induced platelet aggregation from the saliva of Triatoma pallidipennis. , 1994, The Journal of biological chemistry.

[34]  Anna M Wu,et al.  Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.

[35]  T. Caspari,et al.  REVERSAL OF DIGOXIN CARDIAC TOXICITY BY AN ANTICALIN (DIGICAL II) IN THE ANAESTHETIZED GUINEA PIG , 2004 .

[36]  A. Skerra,et al.  The bilin-binding protein of Pieris brassicae. cDNA sequence and regulation of expression reveal distinct features of this insect pigment protein. , 1994, European journal of biochemistry.

[37]  P. Nygren,et al.  Binding proteins from alternative scaffolds. , 2004, Journal of immunological methods.

[38]  K. Mori,et al.  Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia , 2006, Current opinion in nephrology and hypertension.

[39]  R. Strong,et al.  The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. , 2002, Molecular cell.

[40]  Ian R. Drexler,et al.  Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. , 2005, The Journal of clinical investigation.

[41]  K. Ohlsson,et al.  Studies of the release and turnover of a human neutrophil lipocalin. , 1995, Scandinavian journal of clinical and laboratory investigation.

[42]  Huub Schellekens,et al.  Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.

[43]  H. Erdjument-Bromage,et al.  An iron delivery pathway mediated by a lipocalin. , 2002, Molecular cell.

[44]  S. Moestrup,et al.  The endocytic receptor megalin binds the iron transporting neutrophil‐gelatinase‐associated lipocalin with high affinity and mediates its cellular uptake , 2005, FEBS letters.

[45]  I. Korndörfer,et al.  The 1.8-Å Crystal Structure of Human Tear Lipocalin Reveals an Extended Branched Cavity with Capacity for Multiple Ligands* , 2005, Journal of Biological Chemistry.

[46]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.

[47]  A. Korman,et al.  Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques , 2003, The Journal of Immunology.

[48]  P. Ping,et al.  A Membrane Receptor for Retinol Binding Protein Mediates Cellular Uptake of Vitamin A , 2007, Science.

[49]  E. Haber,et al.  Reversal of lethal digoxin toxicity in guinea pigs using monoclonal antibodies and Fab fragments. , 1984, The Journal of pharmacology and experimental therapeutics.

[50]  C. V. Jongeneel,et al.  Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein. , 2005, Cancer immunity.

[51]  I. Korndörfer,et al.  Structural mechanism of specific ligand recognition by a lipocalin tailored for the complexation of digoxigenin. , 2003, Journal of molecular biology.

[52]  Morten Nielsen,et al.  The validity of predicted T-cell epitopes. , 2006, Trends in biotechnology.

[53]  D I Stuart,et al.  Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. , 1999, Molecular cell.

[54]  A. Skerra,et al.  Comparative ligand-binding analysis of ten human lipocalins. , 2006, Biochimica et biophysica acta.

[55]  David Schrama,et al.  Antibody targeted drugs as cancer therapeutics , 2006, Nature Reviews Drug Discovery.

[56]  L. Lögdberg,et al.  Immunocalins: a lipocalin subfamily that modulates immune and inflammatory responses. , 2000, Biochimica et biophysica acta.

[57]  I. Pastan Immunotoxins containing Pseudomonas exotoxin A: a short history , 2003, Cancer Immunology, Immunotherapy.

[58]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[59]  A. Skerra,et al.  Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[60]  J. Andersen,et al.  Nitrophorins and related antihemostatic lipocalins from Rhodnius prolixus and other blood-sucking arthropods. , 2000, Biochimica et biophysica acta.

[61]  J. Blattman,et al.  Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.

[62]  R. Werner,et al.  Economic aspects of commercial manufacture of biopharmaceuticals. , 2004, Journal of biotechnology.

[63]  A. Plückthun,et al.  Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.

[64]  Colin Ratledge,et al.  Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. , 2005, Structure.

[65]  A. Skerra Imitating the humoral immune response. , 2003, Current opinion in chemical biology.

[66]  T. Connolly,et al.  Isolation of an inhibitor selective for collagen-stimulated platelet aggregation from the soft tick Ornithodoros moubata. , 1993, The Journal of biological chemistry.

[67]  B. Redl,et al.  Molecular Cloning of a Novel Lipocalin-1 Interacting Human Cell Membrane Receptor Using Phage Display* , 2001, The Journal of Biological Chemistry.

[68]  Arne Skerra,et al.  Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins". , 2005, Drug discovery today.

[69]  Shizuo Akira,et al.  Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron , 2004, Nature.

[70]  D R Flower,et al.  The lipocalin protein family: structure and function. , 1996, The Biochemical journal.